Glenmark Pharmaceuticals Ltd. (GLENMARK) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 780863,
    "name": "Glenmark Pharma",
    "stock_name": "Glenmark Pharma",
    "full_name": "Glenmark Pharmaceuticals Ltd.",
    "name_url": "stocks-analysis/glenmark-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "2,090.85",
    "chg": -9.45,
    "chgp": "-0.45%",
    "dir": -1,
    "prev_price": "2,100.30",
    "mcapval": "56,471.00 Cr",
    "mcap": "Mid Cap",
    "scripcode": 532296,
    "symbol": "GLENMARK",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE935A01035",
    "curr_date": "Apr 02",
    "curr_time": "",
    "bse_nse_vol": "10.22 lacs",
    "exc_status": "Active",
    "traded_date": "Apr 02, 2026",
    "traded_date_str": "2026 04 02",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/glenmark-pharma-780863-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "text": "Part of MojoOne Strategy",
      "type": "SM",
      "url": "https://www.marketsmojo.com/mojopro/stock-of-the-month",
      "ismore": 0,
      "all_data": [],
      "is_blur": 1,
      "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/glenmark-pharma-780863-0&utm_source=Spage_Score_PartofStrategies"
    }
  },
  "news": {
    "results": [
      {
        "title": "Glenmark Pharmaceuticals Ltd. Hits Intraday Low Amid Price Pressure on 2 Apr 2026",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-ltd-hits-intraday-low-amid-price-pressure-on-2-apr-2026-3929821",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/GlenmarkPharmac_priceRelatedfactors_3929821.png",
        "date": "2026-04-02 09:32:20",
        "description": "Glenmark Pharmaceuticals Ltd. experienced a notable decline today, touching an intraday low of Rs 2,001.1 as the stock faced significant price pressure. The pharmaceutical company underperformed its sector and broader market indices amid a volatile trading session marked by bearish sentiment."
      },
      {
        "title": "Glenmark Pharmaceuticals Ltd. is Rated Buy",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glenmark-pharmaceuticals-ltd-is-rated-buy-3921397",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/GlenmarkPharmac_mojoScore_3921397.png",
        "date": "2026-03-28 10:10:27",
        "description": "Glenmark Pharmaceuticals Ltd. is currently rated 'Buy' by MarketsMOJO, with this rating last updated on 31 January 2026. While the rating was adjusted on that date, the analysis and financial metrics presented here reflect the stock’s current position as of 28 March 2026, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "Glenmark Pharmaceuticals Sees Significant Open Interest Surge Signalling Bullish Market Positioning",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-significant-open-interest-surge-signalling-bullish-market-positioning-3920077",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/GlenmarkPharmac_oi_spurts_by_underlying_3920077.png",
        "date": "2026-03-27 15:00:44",
        "description": "Glenmark Pharmaceuticals Ltd. has witnessed a notable surge in open interest in its derivatives segment, signalling increased market participation and potential directional bets. The stock’s recent outperformance against its sector and broader indices, combined with rising volumes and improved technical positioning, suggests growing investor confidence amid evolving market dynamics."
      },
      {
        "title": "Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Bullish Market Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-sharp-open-interest-surge-amid-bullish-market-momentum-3916513",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/GlenmarkPharmac_oi_spurts_by_underlying_3916513.png",
        "date": "2026-03-25 15:00:49",
        "description": "Glenmark Pharmaceuticals Ltd. has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and potential directional bets. The stock outperformed its sector peers, supported by robust volume and positive price action, reflecting renewed investor confidence in the mid-cap pharmaceutical player."
      },
      {
        "title": "Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Bullish Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-sharp-open-interest-surge-amid-bullish-momentum-3916376",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/GlenmarkPharmac_oi_spurts_by_underlying_3916376.png",
        "date": "2026-03-25 14:00:38",
        "description": "Glenmark Pharmaceuticals Ltd. has witnessed a significant surge in open interest (OI) in its derivatives segment, signalling heightened market activity and shifting investor positioning. The stock’s recent outperformance relative to its sector and the broader market, combined with rising volumes and a notable increase in futures and options value, suggests growing bullish sentiment among traders."
      },
      {
        "title": "Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Mixed Price Action",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-sharp-open-interest-surge-amid-mixed-price-action-3910785",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/GlenmarkPharmac_oi_spurts_by_underlying_3910785.png",
        "date": "2026-03-24 15:00:36",
        "description": "Glenmark Pharmaceuticals Ltd. has witnessed a significant 18.9% surge in open interest in its derivatives segment, signalling heightened market activity despite recent price underperformance. This spike in open interest, coupled with volume patterns and shifting investor positioning, suggests evolving directional bets on the mid-cap pharmaceutical player amid a cautious sector backdrop."
      },
      {
        "title": "Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-sharp-open-interest-surge-amid-mixed-market-signals-3910658",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/GlenmarkPharmac_oi_spurts_by_underlying_3910658.png",
        "date": "2026-03-24 14:00:31",
        "description": "Glenmark Pharmaceuticals Ltd. has witnessed a significant 23.15% surge in open interest in its derivatives segment, signalling heightened market activity and shifting positioning among traders. Despite this, the stock underperformed its sector and broader indices, reflecting a complex interplay of investor sentiment and technical factors."
      },
      {
        "title": "Glenmark Pharmaceuticals Sees Sharp Surge in Open Interest Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-sharp-surge-in-open-interest-amid-mixed-market-signals-3910533",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/GlenmarkPharmac_oi_spurts_by_underlying_3910533.png",
        "date": "2026-03-24 13:00:25",
        "description": "Glenmark Pharmaceuticals Ltd. has witnessed a significant 21.25% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a modest 0.83% gain in the stock price, the underlying dynamics suggest a complex interplay of directional bets and liquidity flows within the mid-cap pharmaceutical sector."
      },
      {
        "title": "Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Mixed Price Action",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-sharp-open-interest-surge-amid-mixed-price-action-3910397",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/GlenmarkPharmac_oi_spurts_by_underlying_3910397.png",
        "date": "2026-03-24 12:00:12",
        "description": "Glenmark Pharmaceuticals Ltd. has witnessed a notable 19.9% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite this, the stock marginally underperformed its sector and broader indices, reflecting a complex interplay between bullish bets and cautious sentiment among traders."
      }
    ],
    "total": 509,
    "sid": "780863",
    "stock_news_url": "https://www.marketsmojo.com/news/glenmark-pharmaceuticals-780863"
  },
  "announcements": [
    {
      "caption": "Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Regulatory Action/ Inspection",
      "datetime": "01-Apr-2026",
      "details": "Disclosure under Regulation 30 of the SEBI (LODR) Regulations 2015 - Regulatory action/Inspection",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "01-Apr-2026",
      "details": "Glenmark Pharmaceuticals Announces Strategic Shift to Direct Commercialization and Distribution of RYALTRIS in the U.S. Significantly Expanding Its Innovative Portfolio. RYALTRIS is Glenmarks first innovative product introduced into the U.S. Market.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "21-Mar-2026",
      "details": "Glenmark Pharmaceuticals Launches GLIPIQ (Semaglutide) in India. Setting a new benchmark in affordability for GLP-1 therapy with weekly treatment starting at Rs. 325",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Glenmark Pharmaceuticals Ltd. has declared <strong>250%</strong> dividend, ex-date: 03 Oct 25",
          "dt": "2025-10-03",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Glenmark Pharmaceuticals Ltd. has announced <strong>1:2</strong> stock split, ex-date: 10 Sep 07",
          "dt": "2007-09-10",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Glenmark Pharmaceuticals Ltd. Hits Intraday Low Amid Price Pressure on 2 Apr 2026

2026-04-02 09:32:20

Glenmark Pharmaceuticals Ltd. experienced a notable decline today, touching an intraday low of Rs 2,001.1 as the stock faced significant price pressure. The pharmaceutical company underperformed its sector and broader market indices amid a volatile trading session marked by bearish sentiment.

Read full news article

Glenmark Pharmaceuticals Ltd. is Rated Buy

2026-03-28 10:10:27

Glenmark Pharmaceuticals Ltd. is currently rated 'Buy' by MarketsMOJO, with this rating last updated on 31 January 2026. While the rating was adjusted on that date, the analysis and financial metrics presented here reflect the stock’s current position as of 28 March 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

Glenmark Pharmaceuticals Sees Significant Open Interest Surge Signalling Bullish Market Positioning

2026-03-27 15:00:44

Glenmark Pharmaceuticals Ltd. has witnessed a notable surge in open interest in its derivatives segment, signalling increased market participation and potential directional bets. The stock’s recent outperformance against its sector and broader indices, combined with rising volumes and improved technical positioning, suggests growing investor confidence amid evolving market dynamics.

Read full news article

Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Bullish Market Momentum

2026-03-25 15:00:49

Glenmark Pharmaceuticals Ltd. has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and potential directional bets. The stock outperformed its sector peers, supported by robust volume and positive price action, reflecting renewed investor confidence in the mid-cap pharmaceutical player.

Read full news article

Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Bullish Momentum

2026-03-25 14:00:38

Glenmark Pharmaceuticals Ltd. has witnessed a significant surge in open interest (OI) in its derivatives segment, signalling heightened market activity and shifting investor positioning. The stock’s recent outperformance relative to its sector and the broader market, combined with rising volumes and a notable increase in futures and options value, suggests growing bullish sentiment among traders.

Read full news article

Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Mixed Price Action

2026-03-24 15:00:36

Glenmark Pharmaceuticals Ltd. has witnessed a significant 18.9% surge in open interest in its derivatives segment, signalling heightened market activity despite recent price underperformance. This spike in open interest, coupled with volume patterns and shifting investor positioning, suggests evolving directional bets on the mid-cap pharmaceutical player amid a cautious sector backdrop.

Read full news article

Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Mixed Market Signals

2026-03-24 14:00:31

Glenmark Pharmaceuticals Ltd. has witnessed a significant 23.15% surge in open interest in its derivatives segment, signalling heightened market activity and shifting positioning among traders. Despite this, the stock underperformed its sector and broader indices, reflecting a complex interplay of investor sentiment and technical factors.

Read full news article

Glenmark Pharmaceuticals Sees Sharp Surge in Open Interest Amid Mixed Market Signals

2026-03-24 13:00:25

Glenmark Pharmaceuticals Ltd. has witnessed a significant 21.25% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a modest 0.83% gain in the stock price, the underlying dynamics suggest a complex interplay of directional bets and liquidity flows within the mid-cap pharmaceutical sector.

Read full news article

Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Mixed Price Action

2026-03-24 12:00:12

Glenmark Pharmaceuticals Ltd. has witnessed a notable 19.9% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite this, the stock marginally underperformed its sector and broader indices, reflecting a complex interplay between bullish bets and cautious sentiment among traders.

Read full news article

View All News